Ublituximab: Somewhat surprisingly, physicians do not regard ublituximab’s activity as differentiated among the CD20 class, with overall efficacy impressions that trail both Ocrevus and Kesimpta. That said, physicians do view ublituximab’s faster infusion regimen as relatively favourable to other CD20s, while also seeing its oral prophylactic regimen as moderately beneficial. Encouragingly, 84% of respondents were somewhat/very likely to recommend patients to switch to ublituximab from existing therapies, largely Ocrevus and Oral DMTs. Assuming approval and launch in 2022, physicians anticipate share of ~15% among high efficacy therapies class by 2026. While use expectations for ublituximab trend somewhat lower to our current estimates (peak sales of ~$2.2B), we believe the anticipated lower price, taken together with increasing physician education on its comparative clinical profile, could result in higher drug uptake over the mid- to longer-term.